Effect of Sulforaphane on Bladder Compliance in a Rat Model of Partial Bladder Outlet Obstruction

Chong Liu, Xiang Wan, Meng Gu, Yanbo Chen, Zhikang Cai, Juan Zhou, Qi Chen, Zhong WangOxidative 2019 · DOI

TL;DR

This study investigates how sulforaphane (SFN), a natural compound, impacts bladder compliance in rats with partial bladder outlet obstruction (BOO). The findings suggest SFN improves bladder function by modulating the balance of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1), and by altering collagen deposition, offering a potential therapeutic avenue for BOO-related bladder dysfunction.

What Problem Does This Paper Address?

Benign prostatic hyperplasia (BPH) is a common condition in older men that can lead to lower urinary tract symptoms (LUTS), often caused by partial bladder outlet obstruction (BOO). BOO can significantly reduce bladder compliance, a measure of how easily the bladder can stretch to accommodate urine, which in turn can lead to kidney dysfunction. This reduced compliance is thought to be linked to changes in the bladder's extracellular matrix (ECM), particularly an increase in collagen deposition. While the imbalance between enzymes that break down ECM (matrix metalloproteinases, MMPs) and their inhibitors (tissue inhibitors of metalloproteinases, TIMPs) is known to play a role, the specific mechanisms and potential therapeutic interventions for BOO-induced bladder compliance changes remain an area of active research. This paper aims to explore the effect of sulforaphane (SFN), a known Nrf2 activator and antioxidant, on bladder compliance in a rat model of BOO and to elucidate the underlying molecular mechanisms.

Methods

The researchers utilized a rat model of partial bladder outlet obstruction (BOO). Male Sprague-Dawley rats were divided into three groups: sham-operated (control), BOO rats, and BOO rats treated with sulforaphane (SFN) intraperitoneally for four weeks.

Key techniques employed include:

  • BOO Model Creation: A standard surgical procedure involving partial obstruction of the urethra was used to induce BOO.
  • Cystometry: This functional assessment was performed on conscious rats to measure urodynamic parameters such as bladder compliance, micturition pressure, and bladder capacity. This is a standard method for evaluating bladder function.
  • Histological Analysis: Bladder tissues were stained with Hematoxylin and Eosin (HE) for general morphology, Masson's trichrome for collagen fiber distribution, and Sirius red for collagen subtypes (Type I and III). This allows for visual assessment of tissue damage and ECM changes.
  • Immunohistochemical Staining: This technique was used to visualize the expression levels of MMP-1 and TIMP-1 within the bladder tissue.
  • Western Blotting: This quantitative method was used to measure the protein expression levels of collagen types I and III, MMP-1, and TIMP-1 in bladder tissue homogenates.

Datasets

Not discussed in the paper. The study relies on experimental data generated from animal models.

Key Insights and Ideas

  • SFN as a Bladder Compliance Enhancer: The most significant finding is that sulforaphane treatment can improve bladder compliance in rats experiencing BOO. This suggests SFN could be a potential therapeutic agent for conditions involving reduced bladder compliance.
  • Modulating the MMP-1/TIMP-1 Axis: The study highlights that BOO disrupts the balance of MMP-1 and TIMP-1, leading to increased ECM deposition. SFN appears to counteract this by increasing MMP-1 and decreasing TIMP-1, thereby promoting ECM breakdown.
  • Collagen Type I/III Ratio Matters: The research demonstrates that BOO increases the ratio of collagen type I to collagen type III. SFN treatment reverses this shift, suggesting it influences the specific types of collagen deposited, which in turn affects bladder elasticity.
  • Beyond Antioxidant Effects: While SFN is known for its antioxidant properties, this study suggests its benefits in BOO extend to direct modulation of ECM remodeling pathways, indicating a multi-faceted therapeutic action.

Key Results

  • Bladder Compliance: BOO significantly decreased bladder compliance, which was partially restored by SFN treatment.
  • Collagen Deposition: BOO led to increased collagen deposition in the bladder. SFN treatment reduced this deposition.
  • Collagen I/III Ratio: The ratio of collagen type I to collagen type III was significantly increased in BOO rats, and SFN treatment reversed this increase.
  • MMP-1 and TIMP-1 Expression: BOO rats showed decreased MMP-1 and increased TIMP-1 expression. SFN treatment ameliorated these changes, increasing MMP-1 and decreasing TIMP-1.
  • Histological Changes: BOO caused observable damage to bladder structure, which was attenuated by SFN treatment.

Limitations and Future Work

The authors acknowledge that extrapolating these findings directly to human patients is a limitation, as the protective effect of SFN might also be due to its general antioxidative and anti-inflammatory properties, not solely its impact on bladder compliance. They suggest that further studies are needed for a comprehensive understanding of SFN's effects. Future research could explore the precise molecular pathways through which SFN influences the MMP-1/TIMP-1 axis and collagen synthesis, and investigate its efficacy in other models of bladder dysfunction or in clinical trials.

Summary updated

Abstract

Sulforaphane suppressed collagen deposition by regulating the MMP-1 and TIMP-1 expression and decreasing the collagen I/III expression ratio in BOO rats and improved bladder compliance.
BibTeX
@inproceedings{liu2019effect,
  author = {Chong Liu and Xiang Wan and Meng Gu and Yanbo Chen and Zhikang Cai and Juan Zhou and Qi Chen and Zhong Wang},
  title = {{Effect of Sulforaphane on Bladder Compliance in a Rat Model of Partial Bladder Outlet Obstruction}},
  booktitle = {Oxidative},
  year = {2019},
  doi = {10.1155/2019/6026719},
}
Figure